- The European Commission has approved Biogen Inc's BIIB Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS).
- Vumerity is next-generation fumarate with the established efficacy and well-characterized safety of Tecfidera (dimethyl fumarate).
- The approval was also based on findings from the EVOLVE-MS-2 Phase 3 study to evaluate the gastrointestinal (GI) tolerability of Vumerity compared to Tecfidera.
- The rate of overall treatment discontinuation was lower in participants treated with Vumerity than those treated with Tecfidera (1.6% compared to 6%, respectively).
- Price Action: BIIB shares are down 3.24% at $263 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
